A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI)- (299AR201-TRANSPIRE)

Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants

Percentage of participants who achieve BPHR at Week 24 (Month 6) (Banff 2022 criteria)

Part A : • MVI score at Week 24 (Month 6) (Banff 2022 criteria) • Percentage of participants who achieve MVI score of 0 at Week 24 (Banff 2022 criteria) • Change in eGFR from Baseline to Week 24 • Percentage of participants in the C4d-positive cohort who achieve BPHR at Week 24 (Month 6) (Banff 2022 criteria), Part B Arm 1:• Percentage of participants who achieve BPHR (Banff 2022 criteria) • MVI score (Banff 2022 criteria) • Percentage of participants who achieve the MVI score of 0 (Banff 2022 criteria) • Change in estimated glomerular filtration rate (eGFR) from Baseline • Time to all-cause allograft loss, Part B Arm 2: • Percentage of participants who achieve BPHR (Banff 2022 criteria) • MVI score (Banff 2022 criteria) • Percentage of participants who achieve MVI score of 0 (Banff 2022 criteria) • Change in eGFR from Week 24 • Time to all-cause allograft loss, Parts A and B: • Incidence and severity of adverse events (AEs) [treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)] • Percentage of participants with TCMR on biopsy at Week 24 and at Week 52 (Banff 2022 criteria) • Laboratory assessments, vital sign measurements, and ECG

No related papers found yet.